



ASX ANNOUNCEMENT

CELLMID CEO PRESENTS AT "BROKERS MEET BIOTECH"

SYDNEY, Wednesday, 18 September 2013: Cellmid Limited (ASX: CDY) provides the following shareholder update, which will be presented at the "Brokers Meet Biotech" luncheon in Perth, on 19th September, by CEO and Managing Director Maria Halasz.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced development programs involve using its anti-midkine antibodies for the treatment of cancer and inflammatory diseases. In addition, Cellmid is commercialising midkine as a biomarker for cancer diagnosis. Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. For further information please see www.cellmid.com.au.

Midkine (MK)

Midkine is a multifunctional growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, because midkine is only present in a disease context, targeting midkine does not harm normal healthy tissues.



CELLMID LIMITED

HIGH GROWTH ASSETS AND SOLID REVENUE GROWTH

September 2013

Maria Halasz CEO

This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition and the effectiveness of the Company's patent protection.

Cellmid Limited (CDY:ASX)

6 MONTH SHARE PRICE PERFORMANCE



KEY STATISTICS

- Share price \$0.028
- Market cap \$17.6M
- Shares on issue 650M
- Options 300M
- Cash (30 June 2013) \$2M
- Top 20: 35%
- 6 month turnover 675M shares (\$23.6M)
- Cash burn \$250K/m. (before revenue)

BOARD

- Dr David King (Chairman)
- Maria Halasz (CEO and MD)
- Graeme Kaufman (NED)
- Martin Rogers (NED)

MANAGEMENT

- Maria Halasz (CEO and MD)
- Darren Jones (Head of Products)
- Koichiro Koike (Business Development)
- Emma Chen (Business Development AU)

Agenda

1. Cellmid's business, assets and key milestones
2. Cancer drugs ready for clinical development
3. Cancer diagnostic products: on market with regular royalty from 2014
4. Consumer health: strong revenue growth in 2014

1. CELLMID'S BUSINESS, ASSETS AND KEY MILESTONES

Business structure

Cellmid

Midkine Cancer Therapeutics

Broad Intellectual property

Validated science

Clinic ready antibody drugs in multiple cancers in 2014

Midkine Cancer Diagnostics

CxBladder launched in USA by licensee in 2013

2nd license with Quest lung cancer

3rd license with Fujikura expected in 1Q2014

Companion biomarker for cancer program

Consumer health

FGF-5 inhibitor OTC hair growth products sold in AU and Japan, to be launched globally in 2014

Pipeline hair growth product in development

Revenue growth in 2014

Midkine (MK) assets – broad portfolio

- **Cellmid owns 78 patents (20 patent families)**
 - Antibodies to treat cancer
 - Composition of matter/method of treatment (MK antibodies)
 - Production of anti-MK mAbs using Mdk^{-/-} mice
 - Early diagnosis of cancer
- **Over 250 peer reviewed publications on MK by Cellmid inventors**
- **Large inventory**
 - 130 highly characterised monoclonal antibodies
 - >4g of purified rhMK protein (\$5M market value)
 - MK knockout mouse (Mdk^{-/-}) model

Milestone timetable

		4Q 2013	1Q 2014	2Q 2014	3Q 2014	4Q 2014	1Q 2015	2Q 2015	3Q 2015	4Q 2015
Cancer Therapeutic	IND enabling studies (start and finish)	★			★					
	Pre-IND meeting			★						
	Phase 1/2a					★				★
Cancer Diagnostics	Fujikura license		★							
	CxBladder royalty				★					
	LungDx (Quest)					★				
Consumer health	Chinese, EU and Indian distributor	★	★	★						
	US distributor						★			


★ Key milestones

The above is subject to a number of internal and external factors including the availability of resources, the results of studies, the timing and effects of regulatory actions, the strength of competition and the effectiveness of the Company's patent protection.

2. MIDKINE CANCER THERAPEUTICS READY FOR CLINICAL DEVELOPMENT IN 2014


The number of publications on midkine continue to grow

Discovered in 1988, subject of >600 scientific papers since



Midkine is a dominant driver of cancer

Highly basic 13kD protein (121 aa)
Two domains (N and C)




- Growth factor prominent in embryogenesis, but barely detectable in healthy adults
- In adults, midkine expression occurs in two settings:
 1. Inflammation
 2. Malignancy
- >90% amino acid identity between mammalian species




Allows strong validation in animal models

MK is highly prognostic of poor survival in gastric cancer




MK-positive IHC
Gastric adenocarcinoma



Zhao et al Mol Med Report 2012

Midkine antibody slows tumor growth

- Midkine antibody inhibits primary tumour growth and slows metastasis in osteosarcoma
- Intra-muscular xenograft (143B cell line)
- IP injection 24h post xenograft, then every 5 days to 42 days (dose 4mg/kg)



Sueyoshi et al Can Lett 2011

Planned Phase 1/2a clinical study

- 4Q2013: Commence IND enabling studies
- 3Q 2014: Pre-IND meeting
- 4Q2014: Commence open label study in multiple solid tumours (colorectal, lung, gastric)
- 3Q2015: Expected early efficacy information
- 4Q2015: Expected completion of phase 1/2a
 - End stage patients with prior chemotherapy
 - 12 patients in 4 groups of 3 each
 - Log 3 dose escalating (4 doses, 1 per week)

3. CANCER DIAGNOSTICS ON MARKET WITH REGULAR ROYALTIES FROM LATE 2014

MK is overexpressed in at least 26 different tumour types – license opportunities

Blank space: not tested

	Breast	Prostate	Ovarian	Cervical	Uterine	Lung (NSC)	Lung (SC)	Lung (brain mets)	Neuroblastoma	Glioblastoma	Medulloblastoma	Primitive neuroectodermal	Meningioma	Neurofibromatosis type I	Gastric	GI stromal	Bladder	Colorectal	Duodenal	Oral SCC	Esophageal SCC	Hepatocellular	Bile Duct	Pancreatic	Thyroid	Osteosarcoma	Renal	CLL
Blood	<	<	<		<	<	<	<	<					<	<	<		<	<	<	<	<	<	<	<			<
Tissue	<	<	<	<	<	<	<	<	<	<	<	<	<		<	<	<	<		<	<	<		<	<	<		
Urine															<		<	<			<	<	<	<	<		<	

Diagnostic pipeline delivering revenue

	PRECLINICAL	CLINICAL	MARKET
CxBladder for bladder cancer (Pacific Edge)	Revenue generating, expect royalties from 2H2014		
MK as an early cancer marker (Japan) Fujikura	Revenue generating, expect royalties from 2015		
Lung cancer diagnostic (Quest)	Revenue generating, expect milestone and royalties post 2014		
MK metastatic colorectal diagnostic	Collaboration with John Hunter Hospital		
MK as a colorectal screening tool	Collaboration with Abcodia		
MK as a marker in glioblastoma	Phase 2 MK as companion marker		

4. CONSUMER HEALTH: STRONG REVENUE GROWTH IN c2014

First clinically validated topical hair growth product in 25 years




Inhibits FGF-5, a protein responsible for hair loss

- 21% increase in hair growth rate*
- 35% reduction in hair loss*
- 12% increase in growing follicles*
- 74% found the treatment beneficial for hair growth*

*Double blinded placebo controlled clinical study

Clinical study results



Australian launch confirmed market potential



	évolis
June 2012	<ul style="list-style-type: none">Launched commercial proof of concept in Australia (website, media, trade)
Dec 2012	<ul style="list-style-type: none">More than 700 pharmacies signed upPositive market response and solid early revenues
May 2013	<ul style="list-style-type: none">Acquired global rights with established Japanese distributionAcquired import permits to China

Chinese import permits in place

- **Chinese import permits for Jo-Ju and Lexilis brands**
- **Second largest hair growth market globally**
- **Imported cosmetic products attract a premium**
- **Cosmetics market is not price sensitive**

Summary

High value cancer therapeutic product pipeline going into phase 1/2a studies in multiple cancer indications

Revenue generating diagnostics division with multiple licenses and regular royalty expected from late 2014

Revenue generating consumer health division with strong growth from emerging markets in 2014



High value assets underpinned by revenue growth

Thank you

www.cellmid.com.au



@mariahalasz